Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 215

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

In Vitro Antifungal Activities of Isavuconazole (BAL4815), Voriconazole, and Fluconazole against 1,007 Isolates of Zygomycete, Candida , Aspergillus , Fusarium , and Scedosporium Species

Open access
Guinea, Jesús, Peláez, Teresa, Recio, Sandra, Torres-Narbona, Marta, Bouza, Emilio · 2008 · Antimicrobial Agents and Chemotherapy

Abstract

Isavuconazole (BAL4815) is a promising novel broad-spectrum triazole in late-stage clinical development that has proven active in vitro against Aspergillus and Candida species. We compared the in vitro activities of this agent with those of voriconazole and fluconazole by the CLSI (formerly NCCLS) M38-A and M27-A2 procedures against a large collection of 1,007 relevant opportunistic fungi collected from 1986 to 2007: Aspergillus spp. ( n = 702), Candida spp. ( n = 218), Zygomycetes ( n = 45), Scedosporium spp. ( n = 22), and Fusarium spp. ( n = 20). All Candida isolates were from patients with candidemia. For isavuconazole, these techniques were also compared with the Etest. Isavuconazole and voriconazole had MICs at which 50% and 90% of isolates were inhibited (MIC 50 and MIC 90 ), respectively, of 1 and 1 μg/ml and 0.5 and 1 μg/ml against Aspergillus spp. and of 0.015 and 0.03 μg/ml and 0.25 and 0.125 μg/ml against Candida spp. (including fluconazole-resistant strains). The MIC 50 partial and complete inhibition end points of isavuconazole and voriconazole against the non- Aspergillus molds were as follows: 1 and 2 μg/ml and 16 and >16 μg/ml against Zygomycetes; 1 and 4 μg/ml and 0.25 and 0.5 μg/ml against Scedosporium apiospermum ; 4 to 16 and >16 μg/ml and 4 to 8 and 16 to >16 μg/ml (ranges) against Scedosporium prolificans ; and 16 and 16 μg/ml and 4 and 4 μg/ml against Fusarium spp. Isavuconazole showed minimal fungicidal concentrations for 50% and 90% of the isolates of 1 and 1 μg/ml against Aspergillus , 16 and >16 μg/ml against Candida , and 4 and >16 μg/ml against Zygomycetes, respectively, and >16 μg/ml against the remaining molds. The Etest proved to be a suitable alternative method for determining the antifungal activities of isavuconazole against Aspergillus and Candida ; the Etest results showed 96% and 93% agreement with the results of the CLSI M38-A and M27-A2 methods, respectively.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/aac.01512-07

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 215

Metadata

Authors
Guinea, J., Peláez, T., Recio, S., Torres-Narbona, M., & Bouza, E.
Venue
Antimicrobial Agents and Chemotherapy
Published
2008-04
Volume
52
Issue
4
Pages
1396-1400
ISSN
  • 0066-4804 (ISSN-L)
  • 1098-6596
OpenAlex
W2058571383
Cited by
215
References
2
FWCI
10.03
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In Vitro Antifungal Activities of Isavuconazole (BAL4815), Voriconazole, and Fluconazole against 1,007 Isolates of Zygomycete, Candida , Aspergillus , Fusarium , and Scedosporium Species. https://app.cochat.ai/papers/10.1128/aac.01512-07
The paper
Guinea, J., Peláez, T., Recio, S., Torres-Narbona, M., & Bouza, E. (2008). In Vitro Antifungal Activities of Isavuconazole (BAL4815), Voriconazole, and Fluconazole against 1,007 Isolates of Zygomycete, Candida , Aspergillus , Fusarium , and Scedosporium Species. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01512-07

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.